Predictors of On Time Series Completion by Patient-, Clinic- and Systems-Level Characteristics.

*<p>Among women with two or more doses and with complete data. Appropriate dosing interval means: the interval between dose 1 and dose 2≥4 weeks but ≤26 weeks, and the interval between dose 2 and dose 3≥12 weeks, and the interval between dose 1 and dose 3≥24 weeks but ≤52 weeks.</p>§<p>Adjusted for significant variables in the univariate model.</p>§§<p>Variable was not significant in the univariate model.</p>†<p>Visit at which the first dose of HPV4 was initiated.</p><p>Bold font indicates Odds Ratios are statistically significant compared to referent.</p

Clinic- and Systems-Level Characteristics for Each HPV4 Dose.

*<p>Other vaccines given at the same time as HPV4 include TDaP, Td, Hep A, HepA/HepB combination, seasonal flu vaccine, meningitis (MCV4), MMR, pneumococcal vaccine, or varicella virus vaccine.</p>†<p>Birth control includes oral contraceptive pills, OrthoEvra® patch, Nuvaring®, or Depo-Provera® injection.</p>‡<p>Prescriptions include 35 classes of pharmacy dispensed prescriptions in all forms (injectable, oral, suppository, topical, or inhaler) and other vaccines received at the visit, excluding HPV4 vaccination.</p><p>CI means confidence intervals.</p

Descriptors of the Vaccinated Population.

†<p>There were no 9 year olds who received HPV4 in this study. The demographics of the 10–13 year olds were highlighted from the adolescent age group patient-level characteristics because they are a broad CDC target group for HPV vaccination.</p>*<p>Documented at any time prior to the first HPV4 dose.</p

Timely Series Completion by Visit Type at Each HPV4 Dose.

*<p>Dosing intervals: dose 1–2≥4 weeks but ≤26 weeks; dose 2–3≥12 weeks; and dose 1–3≥24 weeks but ≤52 weeks.</p

Descriptors of LSIL^* Subjects.

*<p>LSIL means low grade squamous intraepithelial lesion.</p>†<p>CIN means cervical intraepithelial neoplasia grade 1, 2 or 3.</p

Trial profile.

<p>Trial profile.</p

Cells positive and negative for 3q26 gain.

<p>Cells positive (Panel A) or negative (Panel B) for 3q26 gain detected in subjects with LSIL cytology. 3q26 fluorescnce in situ hybridization (FISH) signals are colored gold and control centromeric 7 FISH signals are colored aqua. A positive test contains two or more cells exhibiting more than four 3q26 (gold) FISH signals.</p

Test characteristics of 3q26 gain for women with LSIL cytology for detecting CIN 2/3 using automated and manual review of 3q26 gain analysis.

<p>PPV means positive predictive value.</p><p>NPV means negative predictive value.</p><p>CIN 2/3 means cervical intraepithelial neoplasia grade 2 or 3.</p><p></p

Test characteristics of 3q26 gain for women with LSIL cytology for detecting CIN 2/3 using automated 3q26 gain analysis alone.

<p>Sensitivity = 80% (95% CI: 28, 99).</p><p>Specificity = 89% (95% CI: 76, 96).</p><p>PPV = 44% (95% CI: 14, 79).</p><p>NPV = 98% (95% CI: 87, 100).</p><p>PPV means positive predictive value.</p><p>NPV means negative predictive value.</p><p>CIN 2/3 means cervical intraepithelial neoplasia grade 2 or 3.</p><p></p

Descriptors of females receiving care at the Inner City/Urban Core vs. Rural Safety Net Health Care Locations.

<p>^*There are significantly more white females in the rural location than urban, p = 0.026.</p>§<p>There are significantly more black females in the urban location than rural, p = 0.021.</p><p>There are no significant age or pregnancy history differences between the urban core population and the rural population.</p